DiagnosTear
its TearX platform recently reported interim clinical study results showing excellent correlation between its Red Eye test and quantitative ELISA testing, alongside French regulatory approval and a new clinical study initiated with Alyatec.
- Country
- France
Growth
TearX Red Eye test
Coverage
| CN | EU | US | |
|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Tear-fluid biopsy | diagnostics-medtech | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.